What is Inspire Medical's earnings per share (EPS)?

Inspire Medical (INSP) reported diluted earnings per share of $4.89 for fiscal year 2025. This represents a 179.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Inspire Medical Financials

INSP

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Inspire Medical (INSP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 65/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Inspire Medical has an operating margin of 5.6%, meaning the company retains $6 of operating profit per $100 of revenue. This results in a moderate score of 35/100, indicating healthy but not exceptional operating efficiency. This is up from 4.5% the prior year.

Growth

Inspire Medical's revenue grew 13.6% year-over-year to $912.0M, a solid pace of expansion. This earns a growth score of 56/100.

Leverage

Inspire Medical carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 6.08, Inspire Medical holds $6.08 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

Inspire Medical has a free cash flow margin of 8.6%, earning a moderate score of 47/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns

Inspire Medical's ROE of 18.6% shows moderate profitability relative to equity, earning a score of 52/100. This is up from 7.8% the prior year.

Altman Z-Score Safe

9.14

Inspire Medical scores 9.14, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.6B) relative to total liabilities ($126.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

6/9

Inspire Medical passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed

0.80x

For every $1 of reported earnings, Inspire Medical generates $0.80 in operating cash flow ($117.0M OCF vs $145.4M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage Safe

371.9x

Inspire Medical earns $371.9 in operating income for every $1 of interest expense ($51.0M vs $137K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$912.0M

YoY+13.6%

5Y CAGR+51.2%

Inspire Medical generated $912.0M in revenue in fiscal year 2025. This represents an increase of 13.6% from the prior year.

EBITDA

$64.9M

YoY+52.3%

Inspire Medical's EBITDA was $64.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 52.3% from the prior year.

Net Income

$145.4M

YoY+171.8%

Inspire Medical reported $145.4M in net income in fiscal year 2025. This represents an increase of 171.8% from the prior year.

EPS (Diluted)

$4.89

YoY+179.4%

Inspire Medical earned $4.89 per diluted share (EPS) in fiscal year 2025. This represents an increase of 179.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$78.5M

YoY-13.9%

Inspire Medical generated $78.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 13.9% from the prior year.

Cash & Debt

$104.8M

YoY-30.2%

5Y CAGR-11.3%

Inspire Medical held $104.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

29M

YoY-3.6%

5Y CAGR+1.1%

Inspire Medical had 29M shares outstanding in fiscal year 2025. This represents a decrease of 3.6% from the prior year.

Margins & Returns

Gross Margin

85.4%

YoY+0.7pp

5Y CAGR+0.7pp

Inspire Medical's gross margin was 85.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the prior year.

Operating Margin

5.6%

YoY+1.1pp

5Y CAGR+54.3pp

Inspire Medical's operating margin was 5.6% in fiscal year 2025, reflecting core business profitability. This is up 1.1 percentage points from the prior year.

Net Margin

16.0%

YoY+9.3pp

5Y CAGR+65.5pp

Inspire Medical's net profit margin was 16.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 9.3 percentage points from the prior year.

Return on Equity

18.6%

YoY+10.9pp

5Y CAGR+43.5pp

Inspire Medical's ROE was 18.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 10.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$103.2M

YoY-9.6%

5Y CAGR+31.6%

Inspire Medical invested $103.2M in research and development in fiscal year 2025. This represents a decrease of 9.6% from the prior year.

Share Buybacks

$175.0M

Inspire Medical spent $175.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Capital Expenditures

$38.5M

YoY-1.6%

5Y CAGR+73.4%

Inspire Medical invested $38.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 1.6% from the prior year.

INSP Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$912.0M+13.6%	$802.8M+28.5%	$624.8M+53.2%	$407.9M+74.7%	$233.4M+102.3%	$115.4M
Cost of Revenue	$133.2M+8.3%	$123.0M+27.3%	$96.6M+46.1%	$66.1M+98.7%	$33.3M+88.8%	$17.6M
Gross Profit	$778.8M+14.6%	$679.8M+28.7%	$528.2M+54.6%	$341.7M+70.8%	$200.1M+104.7%	$97.8M
R&D Expenses	$103.2M-9.6%	$114.1M-2.1%	$116.5M+69.8%	$68.6M+83.8%	$37.4M+43.1%	$26.1M
SG&A Expenses	$624.6M+17.9%	$529.6M+17.2%	$452.0M+40.9%	$320.7M+58.3%	$202.6M+58.4%	$127.9M
Operating Income	$51.0M+41.2%	$36.1M+189.6%	-$40.3M+15.4%	-$47.6M-19.4%	-$39.9M+29.1%	-$56.2M
Interest Expense	$137K+522.7%	$22K	$0-100.0%	$1.7M-21.2%	$2.1M+0.5%	$2.1M
Income Tax	-$79.7M-1712.6%	$4.9M+296.5%	$1.2M+103.4%	$613K+751.4%	$72K-37.4%	$115K
Net Income	$145.4M+171.8%	$53.5M+353.0%	-$21.2M+52.9%	-$44.9M-6.8%	-$42.0M+26.5%	-$57.2M
EPS (Diluted)	$4.89+179.4%	$1.75+343.1%	$-0.72+55.0%	$-1.60-3.9%	$-1.54+29.7%	$-2.19

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$269.1M+19.9%	$224.5M+3.4%	$217.1M+7.8%	$201.3M-16.0%	$239.7M+18.0%	$203.2M+3.7%	$195.9M+19.4%	$164.0M
Cost of Revenue	$36.1M+13.5%	$31.8M-8.4%	$34.7M+12.9%	$30.7M-14.7%	$36.0M+11.1%	$32.4M+8.6%	$29.8M+20.5%	$24.8M
Gross Profit	$233.0M+20.9%	$192.7M+5.7%	$182.4M+6.9%	$170.6M-16.3%	$203.7M+19.3%	$170.8M+2.9%	$166.0M+19.2%	$139.3M
R&D Expenses	$24.9M+3.0%	$24.2M-7.6%	$26.2M-5.7%	$27.8M-8.3%	$30.3M+16.3%	$26.1M-9.6%	$28.9M0.0%	$28.9M
SG&A Expenses	$162.0M+1.9%	$158.9M-0.4%	$159.5M+10.6%	$144.3M+2.0%	$141.5M+8.5%	$130.4M-1.3%	$132.1M+5.1%	$125.6M
Operating Income	$46.1M+378.1%	$9.6M+390.8%	-$3.3M-123.3%	-$1.5M-104.7%	$31.9M+122.7%	$14.3M+180.8%	$5.1M+133.5%	-$15.2M
Interest Expense	N/A	$11K+175.0%	$4K	N/A	N/A	$0	$0	N/A
Income Tax	-$85.8M-2470.0%	$3.6M+187.2%	$1.3M+8.0%	$1.2M-17.4%	$1.4M-22.8%	$1.8M+73.7%	$1.1M+62.0%	$650K
Net Income	$136.1M+1270.2%	$9.9M+376.5%	-$3.6M-220.1%	$3.0M-91.5%	$35.2M+90.4%	$18.5M+88.9%	$9.8M+197.9%	-$10.0M
EPS (Diluted)	N/A	$0.34+383.3%	$-0.12-220.0%	$0.10	N/A	$0.60+87.5%	$0.32+194.1%	$-0.34

INSP Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$907.3M+12.2%	$808.4M+19.4%	$676.8M+19.8%	$564.9M+91.4%	$295.1M+4.9%	$281.2M
Current Assets	$583.7M-7.5%	$630.8M+6.2%	$593.7M+12.0%	$530.0M+97.4%	$268.5M-0.5%	$269.9M
Cash & Equivalents	$104.8M-30.2%	$150.2M-19.1%	$185.5M-58.0%	$441.6M+105.9%	$214.5M+12.6%	$190.5M
Inventory	$145.3M+81.3%	$80.1M+136.4%	$33.9M+185.1%	$11.9M-31.0%	$17.2M+103.2%	$8.5M
Accounts Receivable	$119.7M+28.6%	$93.1M+3.5%	$89.9M+46.8%	$61.2M+79.1%	$34.2M+36.4%	$25.1M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$126.2M+6.3%	$118.7M+13.8%	$104.3M+51.4%	$68.9M+4.3%	$66.0M+28.4%	$51.4M
Current Liabilities	$96.1M+8.5%	$88.5M+13.3%	$78.1M+27.7%	$61.2M+48.1%	$41.3M+99.3%	$20.7M
Long-Term Debt	N/A	N/A	N/A	N/A	$24.5M0.0%	$24.5M
Total Equity	$781.2M+13.3%	$689.7M+20.5%	$572.5M+15.4%	$496.0M+116.6%	$229.0M-0.3%	$229.7M
Retained Earnings	-$146.5M+49.8%	-$291.9M+15.5%	-$345.4M-6.5%	-$324.3M-16.1%	-$279.4M-17.7%	-$237.3M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$907.3M+12.3%	$807.7M+0.7%	$802.2M+9.8%	$730.8M-9.6%	$808.4M+1.5%	$796.2M+9.3%	$728.4M+6.2%	$685.8M
Current Assets	$583.7M-0.5%	$586.5M+2.3%	$573.2M+0.3%	$571.7M-9.4%	$630.8M+8.3%	$582.5M-4.1%	$607.2M+6.1%	$572.2M
Cash & Equivalents	$104.8M-7.1%	$112.8M+5.5%	$106.9M+98.4%	$53.9M-64.1%	$150.2M+1.8%	$147.5M-21.6%	$188.0M+7.2%	$175.4M
Inventory	$145.3M+2.5%	$141.8M+16.6%	$121.6M+22.0%	$99.7M+24.5%	$80.1M+18.8%	$67.4M+14.2%	$59.0M+20.5%	$49.0M
Accounts Receivable	$119.7M+10.8%	$108.0M-21.6%	$137.7M+48.6%	$92.6M-0.5%	$93.1M+3.7%	$89.7M+12.6%	$79.7M+10.2%	$72.3M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$126.2M-10.7%	$141.3M+13.6%	$124.4M+30.8%	$95.1M-19.9%	$118.7M+19.1%	$99.6M+10.3%	$90.3M-6.7%	$96.8M
Current Liabilities	$96.1M-13.3%	$110.8M+18.7%	$93.4M+47.1%	$63.5M-28.3%	$88.5M+19.2%	$74.3M+13.1%	$65.7M-9.0%	$72.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$781.2M+17.2%	$666.5M-1.7%	$677.8M+6.6%	$635.7M-7.8%	$689.7M-1.0%	$696.6M+9.2%	$638.1M+8.3%	$589.0M
Retained Earnings	-$146.5M+48.2%	-$282.6M+3.4%	-$292.5M-1.2%	-$288.9M+1.0%	-$291.9M+10.8%	-$327.1M+5.4%	-$345.6M+2.8%	-$355.4M

INSP Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$117.0M-10.2%	$130.2M+428.3%	$24.7M+113.1%	$11.6M+157.5%	-$20.1M+62.1%	-$53.0M
Capital Expenditures	$38.5M-1.6%	$39.1M+65.6%	$23.6M+159.8%	$9.1M+94.9%	$4.7M+90.1%	$2.5M
Free Cash Flow	$78.5M-13.9%	$91.1M+8798.7%	$1.0M-58.6%	$2.5M+110.0%	-$24.8M+55.3%	-$55.5M
Investing Cash Flow	$21.4M+119.0%	-$113.1M+61.6%	-$294.8M-1404.5%	-$19.6M-167.3%	$29.1M-66.4%	$86.6M
Financing Cash Flow	-$183.4M-250.1%	-$52.4M-475.6%	$13.9M-94.1%	$235.1M+1472.6%	$14.9M-88.9%	$134.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$175.0M	$0	$0	$0	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$52.5M-23.4%	$68.5M+2453.1%	$2.7M+140.0%	-$6.7M-109.7%	$69.2M+32.3%	$52.3M+67129.5%	-$78K-100.9%	$8.9M
Capital Expenditures	$10.7M+2.1%	$10.4M+16.0%	$9.0M+7.0%	$8.4M+19.6%	$7.0M-12.2%	$8.0M-35.4%	$12.4M+6.0%	$11.7M
Free Cash Flow	$41.8M-28.0%	$58.1M+1020.1%	-$6.3M+58.2%	-$15.1M-124.3%	$62.2M+40.4%	$44.3M+455.0%	-$12.5M-339.7%	-$2.8M
Investing Cash Flow	-$11.9M-2.3%	-$11.6M-125.0%	$46.6M+3098.2%	-$1.6M-141.3%	$3.8M+103.7%	-$103.0M-1932.2%	$5.6M+128.8%	-$19.5M
Financing Cash Flow	-$48.3M+5.4%	-$51.1M-1481.6%	$3.7M+104.2%	-$87.8M-25.1%	-$70.1M-809.2%	$9.9M+39.6%	$7.1M+822.8%	$768K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$50.0M0.0%	$50.0M	$0-100.0%	$75.0M	$0	$0	$0	$0

INSP Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	85.4%+0.7pp	84.7%+0.1pp	84.5%+0.8pp	83.8%-2.0pp	85.7%+1.0pp	84.7%
Operating Margin	5.6%+1.1pp	4.5%+10.9pp	-6.5%+5.2pp	-11.7%+5.4pp	-17.1%+31.6pp	-48.7%
Net Margin	16.0%+9.3pp	6.7%+10.1pp	-3.4%+7.6pp	-11.0%+7.0pp	-18.0%+31.6pp	-49.6%
Return on Equity	18.6%+10.9pp	7.8%+11.5pp	-3.7%+5.4pp	-9.0%+9.3pp	-18.4%+6.5pp	-24.9%
Return on Assets	16.0%+9.4pp	6.6%+9.8pp	-3.1%+4.8pp	-8.0%+6.3pp	-14.2%+6.1pp	-20.3%
Current Ratio	6.08-1.1	7.13-0.5	7.60-1.1	8.66+2.2	6.50-6.5	13.02
Debt-to-Equity	0.16-0.0	0.17-0.0	0.18+0.0	0.14+0.0	0.110.0	0.11
FCF Margin	8.6%-2.7pp	11.3%+11.2pp	0.2%-0.5pp	0.6%+11.2pp	-10.6%+37.5pp	-48.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	86.6%+0.7pp	85.9%+1.8pp	84.0%-0.7pp	84.8%-0.2pp	85.0%+0.9pp	84.1%-0.7pp	84.8%-0.1pp	84.9%
Operating Margin	17.1%+12.8pp	4.3%+5.8pp	-1.5%-0.8pp	-0.7%-14.0pp	13.3%+6.3pp	7.0%+4.5pp	2.6%+11.9pp	-9.3%
Net Margin	50.6%+46.2pp	4.4%+6.1pp	-1.7%-3.1pp	1.5%-13.2pp	14.7%+5.6pp	9.1%+4.1pp	5.0%+11.1pp	-6.1%
Return on Equity	17.4%+15.9pp	1.5%+2.0pp	-0.5%-1.0pp	0.5%-4.6pp	5.1%+2.5pp	2.7%+1.1pp	1.5%+3.2pp	-1.7%
Return on Assets	15.0%+13.8pp	1.2%+1.7pp	-0.4%-0.9pp	0.4%-4.0pp	4.4%+2.0pp	2.3%+1.0pp	1.3%+2.8pp	-1.5%
Current Ratio	6.08+0.8	5.29-0.8	6.14-2.9	9.01+1.9	7.13-0.7	7.84-1.4	9.25+1.3	7.93
Debt-to-Equity	0.16-0.1	0.21+0.0	0.18+0.0	0.15-0.0	0.17+0.0	0.140.0	0.14-0.0	0.16
FCF Margin	15.5%-10.3pp	25.9%+28.8pp	-2.9%+4.6pp	-7.5%-33.4pp	25.9%+4.1pp	21.8%+28.2pp	-6.4%-4.6pp	-1.7%

Similar Companies

Alphatec Hldgs Inc ATEC

$1.6B

Haemonetics Corp Mass HAE

$2.6B

Procept Biorobotics Corp PRCT

$1.4B

Quidel QDEL

$1.2B

Livanova Plc LIVN

$3.5B

Frequently Asked Questions

What is Inspire Medical's annual revenue?

Inspire Medical (INSP) reported $912.0M in total revenue for fiscal year 2025. This represents a 13.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Inspire Medical's revenue growing?

Inspire Medical (INSP) revenue grew by 13.6% year-over-year, from $802.8M to $912.0M in fiscal year 2025.

Is Inspire Medical profitable?

Yes, Inspire Medical (INSP) reported a net income of $145.4M in fiscal year 2025, with a net profit margin of 16.0%.

What is Inspire Medical's EBITDA?

Inspire Medical (INSP) had EBITDA of $64.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Inspire Medical's gross margin?

Inspire Medical (INSP) had a gross margin of 85.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Inspire Medical's operating margin?

Inspire Medical (INSP) had an operating margin of 5.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Inspire Medical's net profit margin?

Inspire Medical (INSP) had a net profit margin of 16.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Inspire Medical's return on equity (ROE)?

Inspire Medical (INSP) has a return on equity of 18.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Inspire Medical's free cash flow?

Inspire Medical (INSP) generated $78.5M in free cash flow during fiscal year 2025. This represents a -13.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Inspire Medical's operating cash flow?

Inspire Medical (INSP) generated $117.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Inspire Medical's total assets?

Inspire Medical (INSP) had $907.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Inspire Medical's capital expenditures?

Inspire Medical (INSP) invested $38.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Inspire Medical spend on research and development?

Inspire Medical (INSP) invested $103.2M in research and development during fiscal year 2025.

Does Inspire Medical buy back shares?

Yes, Inspire Medical (INSP) spent $175.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Inspire Medical have outstanding?

Inspire Medical (INSP) had 29M shares outstanding as of fiscal year 2025.

What is Inspire Medical's current ratio?

Inspire Medical (INSP) had a current ratio of 6.08 as of fiscal year 2025, which is generally considered healthy.

What is Inspire Medical's debt-to-equity ratio?

Inspire Medical (INSP) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Inspire Medical's return on assets (ROA)?

Inspire Medical (INSP) had a return on assets of 16.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Inspire Medical's Altman Z-Score?

Inspire Medical (INSP) has an Altman Z-Score of 9.14, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Inspire Medical's Piotroski F-Score?

Inspire Medical (INSP) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Inspire Medical's earnings high quality?

Inspire Medical (INSP) has an earnings quality ratio of 0.80x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Inspire Medical cover its interest payments?

Inspire Medical (INSP) has an interest coverage ratio of 371.9x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Inspire Medical?

Inspire Medical (INSP) scores 65 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.